IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v15y2024i1d10.1038_s41467-024-48416-9.html
   My bibliography  Save this article

L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I/II GLORIA trial

Author

Listed:
  • Frank A. Giordano

    (Medical Faculty Mannheim, University of Heidelberg
    DKFZ-Hector Cancer Institute at the University Medical Center Mannheim)

  • Julian P. Layer

    (University of Bonn
    University of Bonn)

  • Sonia Leonardelli

    (University of Bonn)

  • Lea L. Friker

    (University of Bonn
    University of Bonn)

  • Roberta Turiello

    (University of Bonn)

  • Dillon Corvino

    (University of Bonn)

  • Thomas Zeyen

    (University Hospital Bonn)

  • Christina Schaub

    (University Hospital Bonn)

  • Wolf Müller

    (University of Leipzig)

  • Elena Sperk

    (Medical Faculty Mannheim, University of Heidelberg)

  • Leonard Christopher Schmeel

    (University of Bonn)

  • Katharina Sahm

    (DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
    Heidelberg University
    German Cancer Research Center)

  • Christoph Oster

    (University Duisburg-Essen)

  • Sied Kebir

    (University Duisburg-Essen)

  • Peter Hambsch

    (University of Leipzig)

  • Torsten Pietsch

    (University of Bonn)

  • Sotirios Bisdas

    (University College London)

  • Michael Platten

    (DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
    Heidelberg University
    German Cancer Research Center)

  • Martin Glas

    (University Duisburg-Essen)

  • Clemens Seidel

    (University of Leipzig)

  • Ulrich Herrlinger

    (University Hospital Bonn)

  • Michael Hölzel

    (University of Bonn)

Abstract

The chemokine CXCL12 promotes glioblastoma (GBM) recurrence after radiotherapy (RT) by facilitating vasculogenesis. Here we report outcomes of the dose-escalation part of GLORIA (NCT04121455), a phase I/II trial combining RT and the CXCL12-neutralizing aptamer olaptesed pegol (NOX-A12; 200/400/600 mg per week) in patients with incompletely resected, newly-diagnosed GBM lacking MGMT methylation. The primary endpoint was safety, secondary endpoints included maximum tolerable dose (MTD), recommended phase II dose (RP2D), NOX-A12 plasma levels, topography of recurrence, tumor vascularization, neurologic assessment in neuro-oncology (NANO), quality of life (QOL), median progression-free survival (PFS), 6-months PFS and overall survival (OS). Treatment was safe with no dose-limiting toxicities or treatment-related deaths. The MTD has not been reached and, thus, 600 mg per week of NOX-A12 was established as RP2D for the ongoing expansion part of the trial. With increasing NOX-A12 dose levels, a corresponding increase of NOX-A12 plasma levels was observed. Of ten patients enrolled, nine showed radiographic responses, four reached partial remission. All but one patient (90%) showed at best response reduced perfusion values in terms of relative cerebral blood volume (rCBV). The median PFS was 174 (range 58-260) days, 6-month PFS was 40.0% and the median OS 389 (144-562) days. In a post-hoc exploratory analysis of tumor tissue, higher frequency of CXCL12+ endothelial and glioma cells was significantly associated with longer PFS under NOX-A12. Our data imply safety of NOX-A12 and its efficacy signal warrants further investigation.

Suggested Citation

  • Frank A. Giordano & Julian P. Layer & Sonia Leonardelli & Lea L. Friker & Roberta Turiello & Dillon Corvino & Thomas Zeyen & Christina Schaub & Wolf Müller & Elena Sperk & Leonard Christopher Schmeel , 2024. "L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I/II GLORIA trial," Nature Communications, Nature, vol. 15(1), pages 1-14, December.
  • Handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-48416-9
    DOI: 10.1038/s41467-024-48416-9
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-024-48416-9
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1038/s41467-024-48416-9?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Tuomas Tammela & Georgia Zarkada & Elisabet Wallgard & Aino Murtomäki & Steven Suchting & Maria Wirzenius & Marika Waltari & Mats Hellström & Tibor Schomber & Reetta Peltonen & Catarina Freitas & Anto, 2008. "Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation," Nature, Nature, vol. 454(7204), pages 656-660, July.
    2. Elham Karimi & Miranda W. Yu & Sarah M. Maritan & Lucas J. M. Perus & Morteza Rezanejad & Mark Sorin & Matthew Dankner & Parvaneh Fallah & Samuel Doré & Dongmei Zuo & Benoit Fiset & Daan J. Kloosterma, 2023. "Single-cell spatial immune landscapes of primary and metastatic brain tumours," Nature, Nature, vol. 614(7948), pages 555-563, February.
    3. Nourhan Abdelfattah & Parveen Kumar & Caiyi Wang & Jia-Shiun Leu & William F. Flynn & Ruli Gao & David S. Baskin & Kumar Pichumani & Omkar B. Ijare & Stephanie L. Wood & Suzanne Z. Powell & David L. H, 2022. "Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target," Nature Communications, Nature, vol. 13(1), pages 1-18, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Juan Du & Junlei Zhang & Lin Wang & Xun Wang & Yaxing Zhao & Jiaoying Lu & Tingmin Fan & Meng Niu & Jie Zhang & Fei Cheng & Jun Li & Qi Zhu & Daoqiang Zhang & Hao Pei & Guang Li & Xingguang Liang & He, 2023. "Selective oxidative protection leads to tissue topological changes orchestrated by macrophage during ulcerative colitis," Nature Communications, Nature, vol. 14(1), pages 1-17, December.
    2. Caroline S. Jansen & Meghana S. Pagadala & Maria A. Cardenas & Roshan S. Prabhu & Subir Goyal & Chengjing Zhou & Prasanthi Chappa & BaoHan T. Vo & Chengyu Ye & Benjamin Hopkins & Jim Zhong & Adam Klie, 2024. "Pre-operative stereotactic radiosurgery and peri-operative dexamethasone for resectable brain metastases: a two-arm pilot study evaluating clinical outcomes and immunological correlates," Nature Communications, Nature, vol. 15(1), pages 1-15, December.
    3. Augusto Faria Andrade & Alva Annett & Elham Karimi & Danai Georgia Topouza & Morteza Rezanejad & Yitong Liu & Michael McNicholas & Eduardo G. Gonzalez Santiago & Dhana Llivichuzhca-Loja & Arne Gehlhaa, 2024. "Immune landscape of oncohistone-mutant gliomas reveals diverse myeloid populations and tumor-promoting function," Nature Communications, Nature, vol. 15(1), pages 1-17, December.
    4. Gregory Farber & Yanhan Dong & Qiaozi Wang & Mitesh Rathod & Haofei Wang & Michelle Dixit & Benjamin Keepers & Yifang Xie & Kendall Butz & William J. Polacheck & Jiandong Liu & Li Qian, 2024. "Direct conversion of cardiac fibroblasts into endothelial-like cells using Sox17 and Erg," Nature Communications, Nature, vol. 15(1), pages 1-17, December.
    5. Maria Dzamukova & Tobias M. Brunner & Jadwiga Miotla-Zarebska & Frederik Heinrich & Laura Brylka & Mir-Farzin Mashreghi & Anjali Kusumbe & Ralf Kühn & Thorsten Schinke & Tonia L. Vincent & Max Löhning, 2022. "Mechanical forces couple bone matrix mineralization with inhibition of angiogenesis to limit adolescent bone growth," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
    6. Crismita Dmello & Junfei Zhao & Li Chen & Andrew Gould & Brandyn Castro & Victor A. Arrieta & Daniel Y. Zhang & Kwang-Soo Kim & Deepak Kanojia & Peng Zhang & Jason Miska & Ragini Yeeravalli & Karl Hab, 2023. "Checkpoint kinase 1/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade," Nature Communications, Nature, vol. 14(1), pages 1-18, December.
    7. Fatima Khan & Yiyun Lin & Heba Ali & Lizhi Pang & Madeline Dunterman & Wen-Hao Hsu & Katie Frenis & R. Grant Rowe & Derek A. Wainwright & Kathleen McCortney & Leah K. Billingham & Jason Miska & Craig , 2024. "Lactate dehydrogenase A regulates tumor-macrophage symbiosis to promote glioblastoma progression," Nature Communications, Nature, vol. 15(1), pages 1-20, December.
    8. Jeremiah Bernier-Latmani & Cristina Mauri & Rachel Marcone & François Renevey & Stephan Durot & Liqun He & Michael Vanlandewijck & Catherine Maclachlan & Suzel Davanture & Nicola Zamboni & Graham W. K, 2022. "ADAMTS18+ villus tip telocytes maintain a polarized VEGFA signaling domain and fenestrations in nutrient-absorbing intestinal blood vessels," Nature Communications, Nature, vol. 13(1), pages 1-17, December.
    9. Ki Oh & Yun Jae Yoo & Luke A. Torre-Healy & Manisha Rao & Danielle Fassler & Pei Wang & Michael Caponegro & Mei Gao & Joseph Kim & Aaron Sasson & Georgios Georgakis & Scott Powers & Richard A. Moffitt, 2023. "Coordinated single-cell tumor microenvironment dynamics reinforce pancreatic cancer subtype," Nature Communications, Nature, vol. 14(1), pages 1-13, December.
    10. Yuanning Zheng & Francisco Carrillo-Perez & Marija Pizurica & Dieter Henrik Heiland & Olivier Gevaert, 2023. "Spatial cellular architecture predicts prognosis in glioblastoma," Nature Communications, Nature, vol. 14(1), pages 1-16, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-48416-9. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.